Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
PhaseBio Pharmaceuticals, Inc. logo — We're developing novel therapies to treat orphan diseases, w...

PhaseBio Pharmaceuticals, Inc.

We're developing novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary disorders.

Founded 2002 United States Malvern, United States 10 employees Post Ipo Equity Total: $324.30M Biotechnology, Medical Devices +1

General Information

Company Name PhaseBio Pharmaceuticals, Inc.
Founded Year 2002
Location United States Malvern, United States +2
Founders / Decision Makers
Team member Team member
Employees 10
Industries Biotechnology, Medical Devices, Pharmaceutical
Funding Stage Post Ipo Equity
Social

Get notified when PhaseBio Pharmaceuticals, Inc. moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About PhaseBio Pharmaceuticals, Inc.

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for cardiovascular and cardiopulmonary diseases. The company's pipeline consists of bentracimab (PB2452), a reversal agent for the antiplatelet therapy ticagrelor; pemziviptadil (PB1046), a vasoactive intestinal peptide receptor agonist for pulmonary arterial hypertension; and PB6440, an oral agent for resistant hypertension. These therapies leverage PhaseBio's proprietary elastin-like polypeptide technology platform to enable less-frequent dosing and improved pharmacokinetics. Notably, the company's approach holds promise for treating orphan diseases. PhaseBio leverages its technology to drive both internal and partnership drug-development opportunities. Established in 2002 and headquartered in the United States, PhaseBio received a significant $64.40M Post-IPO Equity investment on 18 March 2021. This investment indicates confidence in PhaseBio's potential to address unmet medical needs related to cardiopulmonary disorders. The company's focus on novel therapies and its successful funding round position it as an intriguing prospect for venture capital consideration. With a dedicated approach to orphan diseases and a robust pipeline, PhaseBio presents an opportunity for investors seeking to support innovative solutions in the biotechnology and pharmaceutical sectors.

Taxonomy: Biopharmaceuticals, Clinical-stage company, Orphan diseases, Cardiopulmonary disorders, Elastin-like polypeptide technology, Novel therapies, Ticagrelor reversal agent, Pulmonary arterial hypertension, Vasoactive intestinal peptide, Resistant hypertension, Type 2 diabetes, Obesity, Heart failure, Drug development, Clinical trials

Funding Rounds & Investors (11)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• - 18 Mar 2021
Post-IPO Equity •••••• 1 •••• •••• 13 Jan 2020
Series D •••••• 9
Investor Investor Investor Investor Investor
•••• •••• 		05 Sep 2018
Grant •••••• 1 •••• •••• 27 Feb 2018
Debt Financing •••••• 1 •••• •••• 29 Nov 2017

View All 11 Funding Rounds

PhaseBio Pharmaceuticals, Inc. Alternatives & Competitors

PhaseBio Pharmaceuticals, Inc. vs
Gossamer Bio
Gossamer Bio United States

Vision * Connection * Innovation

Post Ipo Equity
159 employees
Biotechnology, Health Care
PhaseBio Pharmaceuticals, Inc. vs
Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc. United States

Public, clinical-stage biopharmaceutical company committed to developing best-in-class, novel therap...

IPO
128 employees
Biopharma, Biotechnology
PhaseBio Pharmaceuticals, Inc. vs
Mercator MedSystems, Inc.
Mercator MedSystems, Inc.

Mercator MedSystems, Inc., is a medical technology company focused on the treatment of peripheral ar...

Series D
16 employees
Biotechnology, Health Care

FAQ About PhaseBio Pharmaceuticals, Inc.

We're developing novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary disorders.
PhaseBio Pharmaceuticals, Inc. was founded in 2002.
PhaseBio Pharmaceuticals, Inc. is headquartered in Malvern, United States.
PhaseBio Pharmaceuticals, Inc. operates in the following industries: Biotechnology, Medical Devices, Pharmaceutical.
PhaseBio Pharmaceuticals, Inc. has approximately 10 employees.
PhaseBio Pharmaceuticals, Inc. has completed 11 funding rounds, raising a total of $324.30M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to PhaseBio Pharmaceuticals, Inc. include Gossamer Bio, Mineralys Therapeutics, Inc., Mercator MedSystems, Inc., Liquidia Corporation, AllRock Bio. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
PhaseBio Pharmaceuticals, Inc. and Gossamer Bio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors PhaseBio Pharmaceuticals, Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes